Dr. Lin's research focuses on improving outcomes for patients with GI malignancies through clinical trials and translational research. He has been involved in studies evaluating the efficacy of various treatments for liver and pancreatic cancers . His work aims to develop innovative treatment options for both early-stage and advanced GI cancers to improve patient outcomes
Daniel Lin, MD, MSc
Director, Clinical Outpatient Operations
Medical Director, Honickman Infusion Center
Deputy Director, Sydney Kimmel Cancer Center - Liver Cancer service Line
Assistant Professor
Contact Information
Honickman Center
1101 Chestnut Street
14th Floor
Philadelphia, PA 19107
215-955-8874
215-503-3408 fax
Director, Clinical Outpatient Operations
Medical Director, Honickman Infusion Center
Deputy Director, Sydney Kimmel Cancer Center - Liver Cancer service Line
Assistant Professor
RESEARCH & CLINICAL INTEREST
Education
Medical School
Boston University, Boston Massachusetts, MA - 2010
Residency
Albert Einstein Montefiore Medical Center, Bronx, NY
Fellowship
New York University Medical Center, New York, NY
Most Recent Peer-Reviewed Publications
- Advances in Immunotherapy in Hepatocellular Carcinoma
- Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma
- Liposomal eribulin (E7389-LF) plus nivolumab: a potential treatment option for patients with advanced gastric cancer?
- Complete Pathologic Response to Gemcitabine and Oxaliplatin Chemotherapy After Prior Therapies in a Patient With Hepatocellular Carcinoma and Peritoneal Metastases Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
- Race/ethnicity and socioeconomic position in emergency department utilization in patients with hepatocellular carcinoma
Board Certification
Internal Medicine